Massive new database aims to unlock secrets of rare pancreatic cancer
NCT ID NCT07183280
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is creating a large, real-world database for a rare pancreatic tumor called solid pseudopapillary neoplasm (SPN). Researchers will collect data from 2,000 participants to track long-term outcomes like survival and recurrence. The goal is to provide high-quality evidence to improve future clinical care and research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this database could provide high-quality evidence to guide better treatments and outcomes for people with this rare pancreatic tumor.
- What could go wrong
- This is an observational database study, not a treatment trial. It will not directly test any new therapy, and results depend on data quality and follow-up compliance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Dec 2041
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
To establish and maintain a reliable multicenter real-world database for pancreatic SPN, providing high-quality data and evidence-based support for clinical/translational research.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * No restrictions on age, gender, or performance status; * Pathologically/cytologically confirmed SPN; * Compliance with follow-up requirements; Exclusion Criteria: * Non-neoplastic pancreatic lesions; * Non-pancreatic primary tumors; * Non-compliance with follow-up;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid pseudopapillary neoplasm of the pancreas are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai Cancer Center
RECRUITINGShanghai, Special Administrative Region, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.